Injective CEO Eric Chen expects US INJ ETFs to launch sooner than 2027
Injective-linked US ETF applications have advanced, with two filings now in motion. One piece says Injective CEO Eric Chen expects US INJ ETFs to launch before 2027, while another notes that the 21Shares Injective ETF and the Canary Staked INJ ETF are the two applications tied to INJ.
What this rests on
What it means
Each sentence links inside to the piece that supports it.
If US investors follow these filings, the people most likely to notice first are INJ holders, ETF watchers, and market participants tracking US-listed crypto products. The development centers on two named applications and an expectation from Eric Chen that launch could come before 2027, so the immediate effect is that the product path is now more concrete than a vague future possibility.
In practice, the situation now includes two US ETF applications tied to INJ that have advanced, which means the process has moved into a more active phase than before. What remains the same is that these are still applications rather than launched funds, so the product itself is not yet available in the market.
Market reaction
How the story was built
Every piece in order, with the time its news medium declares — if it is not believable we use ours and say so — and what it added to what was already known at that point. Arriving first is not the same as adding something.
Crypto Briefing
context
Has this happened before?
Nothing comparable yet.